Skip to main content
. 2014 May 27;5(11):3895–3906. doi: 10.18632/oncotarget.2019

Figure 3. Cumulative overall survival (OS) and recurrence-free survival (RFS) curves of 69 sorafenib-administered patients with high or low HTATIP2 density and microvessel density (MVD) as well as their combination in cohort 2.

Figure 3

(A and B) High HTATIP2 and (C and D) low MVD were associated with shortened OS and RFS. (E and F) The combination of high HTATIP2 and low MVD indicated the worst survival.